CoChat
Sign Up
Cited by 819

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

RNA-Based Therapeutics: Current Progress and Future Prospects

Burnett, John C., Rossi, John J.·2012·Chemistry & Biology
DOI 10.1016/j.chembiol.2011.12.008PMC PMC3269031
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chembiol.2011.12.008

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 83

  1. Alvarez, 2009, RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy, Antimicrob. Agents Chemother., 53, 3952, 10.1128/AAC.00014-09 · DOI
  2. Amado, 2004, Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients, Hum. Gene Ther., 15, 251, 10.1089/104303404322886101 · DOI
  3. Amarzguioui, 2008, Principles of Dicer substrate (D-siRNA) design and function, Methods Mol. Biol., 442, 3, 10.1007/978-1-59745-191-8_1 · DOI
  4. Bartlett, 2007, Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging, Proc. Natl. Acad. Sci. USA, 104, 15549, 10.1073/pnas.0707461104 · DOI
  5. Beisel, 2011, Design of small molecule-responsive microRNAs based on structural requirements for Drosha processing, Nucleic Acids Res., 39, 2981, 10.1093/nar/gkq954 · DOI
  6. Bennett, 2010, RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform, Annu. Rev. Pharmacol. Toxicol., 50, 259, 10.1146/annurev.pharmtox.010909.105654 · DOI
  7. Berk, 2006, An editor's look-back, Hepatology, 43, S13, 10.1002/hep.21056 · DOI
  8. Bernstein, 2001, Role for a bidentate ribonuclease in the initiation step of RNA interference, Nature, 409, 363, 10.1038/35053110 · DOI
  9. Bouchard, 2010, Discovery and development of therapeutic aptamers, Annu. Rev. Pharmacol. Toxicol., 50, 237, 10.1146/annurev.pharmtox.010909.105547 · DOI
  10. Burnett, 2009, Stem cells, ribozymes and HIV, Gene Ther., 16, 1178, 10.1038/gt.2009.86 · DOI
  11. Burnett, 2011, Current progress of siRNA/shRNA therapeutics in clinical trials, Biotechnol. J., 6, 1130, 10.1002/biot.201100054 · DOI
  12. Castanotto, 2009, The promises and pitfalls of RNA-interference-based therapeutics, Nature, 457, 426, 10.1038/nature07758 · DOI
  13. Castanotto, 2007, Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC, Nucleic Acids Res., 35, 5154, 10.1093/nar/gkm543 · DOI
  14. Chen, 2008, Aptamer-based endocytosis of a lysosomal enzyme, Proc. Natl. Acad. Sci. USA, 105, 15908, 10.1073/pnas.0808360105 · DOI
  15. Cho, 2009, Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth, Proc. Natl. Acad. Sci. USA, 106, 7137, 10.1073/pnas.0812317106 · DOI
  16. Cohen, 2010, First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention, Circulation, 122, 614, 10.1161/CIRCULATIONAHA.109.927756 · DOI
  17. Dannull, 2007, Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity, Blood, 110, 4341, 10.1182/blood-2007-04-083188 · DOI
  18. Davidson, 2011, Current prospects for RNA interference-based therapies, Nat. Rev. Genet., 12, 329, 10.1038/nrg2968 · DOI
  19. Davis, 2010, Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles, Nature, 464, 1067, 10.1038/nature08956 · DOI
  20. Dejneka, 2008, Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes, Mol. Vis., 14, 997
  21. Delebecque, 2011, Organization of intracellular reactions with rationally designed RNA assemblies, Science, 333, 470, 10.1126/science.1206938 · DOI
  22. DeVincenzo, 2010, A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus, Proc. Natl. Acad. Sci. USA, 107, 8800, 10.1073/pnas.0912186107 · DOI
  23. DiGiusto, 2010, RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma, Sci. Transl. Med., 2, 36ra43, 10.1126/scitranslmed.3000931 · DOI
  24. Ebert, 2010, MicroRNA sponges: progress and possibilities, RNA, 16, 2043, 10.1261/rna.2414110 · DOI · Paper page
  25. Ellington, 1990, In vitro selection of RNA molecules that bind specific ligands, Nature, 346, 818, 10.1038/346818a0 · DOI
  26. Garzon, 2010, Targeting microRNAs in cancer: rationale, strategies and challenges, Nat. Rev. Drug Discov., 9, 775, 10.1038/nrd3179 · DOI
  27. Grimm, 2010, Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver, J. Clin. Invest., 120, 3106, 10.1172/JCI43565 · DOI · Paper page
  28. Guo, 2002, Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria, J. Biol. Chem., 277, 13430, 10.1074/jbc.M108029200 · DOI
  29. Haasnoot, 2009, Nucleic acids-based therapeutics in the battle against pathogenic viruses, Handb. Exp. Pharmacol., 243, 10.1007/978-3-540-79086-0_9 · DOI
  30. Han, 2006, Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex, Cell, 125, 887, 10.1016/j.cell.2006.03.043 · DOI
  31. Hicke, 2006, Tumor targeting by an aptamer, J. Nucl. Med., 47, 668
  32. Huang, 2003, Crystal structure of NF-kappaB (p50)2 complexed to a high-affinity RNA aptamer, Proc. Natl. Acad. Sci. USA, 100, 9268, 10.1073/pnas.1632011100 · DOI
  33. Hwang, 2010, A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer, J. Nucl. Med., 51, 98, 10.2967/jnumed.109.069880 · DOI
  34. Keefe, 2010, Aptamers as therapeutics, Nat. Rev. Drug Discov., 9, 537, 10.1038/nrd3141 · DOI · Paper page
  35. Kim, 2005, Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy, Nat. Biotechnol., 23, 222, 10.1038/nbt1051 · DOI
  36. Kleinman, 2008, Sequence- and target-independent angiogenesis suppression by siRNA via TLR3, Nature, 452, 591, 10.1038/nature06765 · DOI
  37. Kobayashi, 2005, Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors, Cancer Chemother. Pharmacol., 56, 329, 10.1007/s00280-004-0968-x · DOI
  38. Kohn, 1999, A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children, Blood, 94, 368, 10.1182/blood.V94.1.368.413a47_368_371 · DOI
  39. Koldehoff, 2007, Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia, Clin. Exp. Med., 7, 47, 10.1007/s10238-007-0125-z · DOI
  40. Kruger, 1982, Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena, Cell, 31, 147, 10.1016/0092-8674(82)90414-7 · DOI · Paper page
  41. Lanford, 2010, Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection, Science, 327, 198, 10.1126/science.1178178 · DOI · Paper page
  42. Lares, 2010, RNAi and small interfering RNAs in human disease therapeutic applications, Trends Biotechnol., 28, 570, 10.1016/j.tibtech.2010.07.009 · DOI · Paper page
  43. Leachman, 2010, First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder, Mol. Ther., 18, 442, 10.1038/mt.2009.273 · DOI
  44. Li, 2010, Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery, J. Control. Release, 142, 416, 10.1016/j.jconrel.2009.11.008 · DOI
  45. Li, 2005, Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy, Mol. Ther., 12, 900, 10.1016/j.ymthe.2005.07.524 · DOI
  46. Liang, 2011, Engineering biological systems with synthetic RNA molecules, Mol. Cell, 43, 915, 10.1016/j.molcel.2011.08.023 · DOI
  47. Macpherson, 2005, Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients, J. Gene Med., 7, 552, 10.1002/jgm.705 · DOI
  48. Maples, 2010, FANG Vaccine: Autologous Tumor Cell Vaccine Genitically Modified to Express GM-CSF and Block Production of Furin, BioProcessing Journal, 8, 4, 10.12665/J84.Maples · DOI
  49. Martinez, 2002, Single-stranded antisense siRNAs guide target RNA cleavage in RNAi, Cell, 110, 563, 10.1016/S0092-8674(02)00908-X · DOI
  50. Mashima, 2009, Unique quadruplex structure and interaction of an RNA aptamer against bovine prion protein, Nucleic Acids Res., 37, 6249, 10.1093/nar/gkp647 · DOI
  51. McNamara, 2006, Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras, Nat. Biotechnol., 24, 1005, 10.1038/nbt1223 · DOI
  52. Melnikova, 2007, RNA-based therapies, Nat. Rev. Drug Discov., 6, 863, 10.1038/nrd2443 · DOI
  53. Michienzi, 2003, RNA-mediated inhibition of HIV in a gene therapy setting, Ann. N Y Acad. Sci., 1002, 63, 10.1196/annals.1281.008 · DOI
  54. Neff, 2011, An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice, Sci. Transl. Med., 3, 66ra66, 10.1126/scitranslmed.3001581 · DOI
  55. Nguyen, 2009, Transkingdom RNA interference (tkRNAi): a novel method to induce therapeutic gene silencing, Methods Mol. Biol., 514, 27, 10.1007/978-1-60327-527-9_3 · DOI
  56. Pastor, 2010, Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay, Nature, 465, 227, 10.1038/nature08999 · DOI
  57. Peer, 2011, Special delivery: targeted therapy with small RNAs, Gene Ther., 18, 1127, 10.1038/gt.2011.56 · DOI
  58. Phan, 2011, Structure-function studies of FMRP RGG peptide recognition of an RNA duplex-quadruplex junction, Nat. Struct. Mol. Biol., 18, 796, 10.1038/nsmb.2064 · DOI
  59. Rand, 2005, Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation, Cell, 123, 621, 10.1016/j.cell.2005.10.020 · DOI
  60. Reagan-Shaw, 2005, Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer, FASEB J., 19, 611, 10.1096/fj.04-2910fje · DOI
  61. Samuel-Abraham, 2010, Staying on message: design principles for controlling nonspecific responses to siRNA, FEBS J., 277, 4828, 10.1111/j.1742-4658.2010.07905.x · DOI
  62. Sandberg, 2001, Safety analysis of a phase I study of HEPTAZYME (TM), a nuclease resistant ribozyme targeting hepatitis C (HCV) RNA, Hepatology, 34, 333a
  63. Sanghvi, 2011, A status update of modified oligonucleotides for chemotherapeutics applications, Curr. Protoc. Nucleic Acid Chem., 10.1002/0471142700.nc0401s46 · DOI
  64. Santel, 2010, Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models, Clin. Cancer Res., 16, 5469, 10.1158/1078-0432.CCR-10-1994 · DOI
  65. Scherer, 2003, Approaches for the sequence-specific knockdown of mRNA, Nat. Biotechnol., 21, 1457, 10.1038/nbt915 · DOI
  66. Serganov, 2007, Ribozymes, riboswitches and beyond: regulation of gene expression without proteins, Nat. Rev. Genet., 8, 776, 10.1038/nrg2172 · DOI
  67. Shukla, 2010, Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook, ChemMedChem, 5, 328, 10.1002/cmdc.200900444 · DOI
  68. Soutschek, 2004, Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs, Nature, 432, 173, 10.1038/nature03121 · DOI
  69. Sussman, 2000, A water channel in the core of the vitamin B(12) RNA aptamer, Structure, 8, 719, 10.1016/S0969-2126(00)00159-3 · DOI
  70. Thiel, 2009, Therapeutic applications of DNA and RNA aptamers, Oligonucleotides, 19, 209, 10.1089/oli.2009.0199 · DOI
  71. Tiemann, 2010, Dual-targeting siRNAs, RNA, 16, 1275, 10.1261/rna.2005710 · DOI
  72. Tiemann, 2009, RNAi-based therapeutics-current status, challenges and prospects, EMBO Mol Med, 1, 142, 10.1002/emmm.200900023 · DOI
  73. Tong, 2002, Preliminary analysis of a phase II study of Heptazyme (TM), a nuclease resistant ribozyme targeting hepatitis C virus (HCV) RNA, Hepatology, 36, 360a
  74. Tuerk, 1990, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase, Science, 249, 505, 10.1126/science.2200121 · DOI
  75. Vaishnaw, 2011, RNAi in humans: phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement, Nucleic Acid Therapeutics, 21, A44
  76. Vaishnaw, 2010, A status report on RNAi therapeutics, Silence, 1, 14, 10.1186/1758-907X-1-14 · DOI
  77. Watts, 2010, Clinical status of duplex RNA, Bioorg. Med. Chem. Lett., 20, 3203, 10.1016/j.bmcl.2010.03.109 · DOI
  78. Weng, 2005, A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors, Mol. Cancer Ther., 4, 948, 10.1158/1535-7163.MCT-04-0210 · DOI
  79. Wieland, 2010, Aptazyme-mediated regulation of 16S ribosomal RNA, Chem. Biol., 17, 236, 10.1016/j.chembiol.2010.02.012 · DOI
  80. Wong-Staal, 1998, A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA, Hum. Gene Ther., 9, 2407, 10.1089/hum.1998.9.16-2407 · DOI
  81. Xiang, 2009, In vitro and in vivo gene silencing by TransKingdom RNAi (tkRNAi), Methods Mol. Biol., 487, 147
  82. Zamora, 2011, RNA interference therapy in lung transplant patients infected with respiratory syncytial virus, Am. J. Respir. Crit. Care Med., 183, 531, 10.1164/rccm.201003-0422OC · DOI
  83. Zhang, 2010, Strategies in designing multigene expression units to downregulate HIV-1, Methods Mol. Biol., 623, 123, 10.1007/978-1-60761-588-0_8 · DOI

Cited by

Sorted by citations

Metadata

Authors
Burnett, J. C., & Rossi, J. J.
Venue
Chemistry & Biology
Publisher
Elsevier BV
Published
2012-01
Volume
19
Issue
1
Pages
60-71
ISSN
1074-5521
DOI
10.1016/j.chembiol.2011.12.008
PMC
PMC3269031
Cited by
819
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review